To get a sense of who is truly in control of Bristol-Myers Squibb Company (NYSE:BMY), it is important to understand the ...

Bristol Myers Squibb said on Friday its blockbuster drug Reblozyl in combination with another therapy failed to meet the main ...

Bristol Myers Squibb said on Friday its blockbuster drug Reblozyl in combination with another therapy failed to meet the main ...

(Reuters) -Bristol Myers Squibb said on Friday its blockbuster drug Reblozyl in combination with another therapy failed to ...

Bristol Myers Squibb & Co. (NYSE:BMY) on Friday announced topline results from the Phase 3 INDEPENDENCE trial evaluating ...

The reduced rate will still be almost 10 times the average monthly out-of-pocket costs paid by commercially insured patients.

Bristol Myers Squibb (BMY) stock slips as its anemia drug Reblozyl misses primary goal in a Phase 3 trial for myelofibrosis, ...

Bristol Myers and Pfizer will sell Eliquis directly to U.S. patients at a discounted rate with transparent pricing and ...

Bristol Myers on Friday said the Phase 3 study of Reblozyl with concomitant janus-kinase-inhibitor therapy didn't meet its primary endpoint of red-blood-cell transfusion independence in adults with ...

Pfizer and Bristol Myers Squibb have launched a direct-to-patient program offering their blood thinner Eliquis at a 40% discount for cash-paying patients.  The list price for Eliquis (apixaban) is ...

The direct-to-consumer (DTC) platform – called Eliquis 360 Support – will offer Eliquis (apixaban) to patients who pay for ...

Despite a phase 3 flop, Bristol Myers Squibb—encouraged by “clinically meaningful results” and bruised by three other recent pivotal trial failures—still plans to discuss a potential approval filin | ...